| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.6M | -37.9% | +164.5% |
| SG&A Expense | $2.3M | -23.8% | -63.9% |
| Operating Income | -$5.9M | +33.0% | +0.8% |
| Net Income | -$5.5M | -232.6% | +55.7% |
| EPS (Basic) | -$0.59 | -215.7% | -156.5% |
| EPS (Diluted) | -$0.59 | +41.0% | -156.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.4M | +3.7% | -42.2% |
| Short-term Investments | $15.0M | -26.1% | — |
| Current Assets | $38.4M | -10.9% | -19.8% |
| Total Assets | $39.0M | -10.8% | -24.0% |
| Current Liabilities | $11.0M | +3.4% | +10.0% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.8M | — | — |
| Investing Cash Flow | -$15.1M | — | — |
| Financing Cash Flow | $22.7M | — | — |
| $11.2M |
| +3.1% |
| -78.0% |
| Stockholders' Equity | $27.9M | -15.4% | +3841.4% |